Neurogene Statistics

Total Valuation

Neurogene has a market cap or net worth of $301.28 million. The enterprise value is $37.73 million.

Market Cap	301.28M
Enterprise Value	37.73M

Important Dates

The last earnings date was Monday, August 11, 2025, after market close.

Earnings Date	Aug 11, 2025
Ex-Dividend Date	n/a

Share Statistics

Neurogene has 14.27 million shares outstanding. The number of shares has increased by 52.10% in one year.

Current Share Class	14.27M
Shares Outstanding	14.27M
Shares Change (YoY)	+52.10%
Shares Change (QoQ)	+0.28%
Owned by Insiders (%)	10.91%
Owned by Institutions (%)	47.20%
Float	3.36M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.10
P/TBV Ratio	1.10
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 18.07, with a Debt / Equity ratio of 0.04.

Current Ratio	18.07
Quick Ratio	17.86
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-11,961.50

Financial Efficiency

Return on equity (ROE) is -39.41% and return on invested capital (ROIC) is -26.40%.

Return on Equity (ROE)	-39.41%
Return on Assets (ROA)	-25.07%
Return on Invested Capital (ROIC)	-26.40%
Return on Capital Employed (ROCE)	-33.95%
Revenue Per Employee	n/a
Profits Per Employee	-$788,729
Employee Count	107
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -39.15% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-39.15%
50-Day Moving Average	20.50
200-Day Moving Average	21.14
Relative Strength Index (RSI)	50.75
Average Volume (20 Days)	118,050

Short Selling Information

The latest short interest is 2.59 million, so 18.17% of the outstanding shares have been sold short.

Short Interest	2.59M
Short Previous Month	2.55M
Short % of Shares Out	18.17%
Short % of Float	77.13%
Short Ratio (days to cover)	13.51

Income Statement

Revenue	n/a
Gross Profit	-68.76M
Operating Income	-95.69M
Pretax Income	-55.44M
Net Income	-84.39M
EBITDA	-92.56M
EBIT	-95.69M
Earnings Per Share (EPS)	-$4.30

Full Income Statement

Balance Sheet

The company has $274.52 million in cash and $10.97 million in debt, giving a net cash position of $263.55 million or $18.47 per share.

Cash & Cash Equivalents	274.52M
Total Debt	10.97M
Net Cash	263.55M
Net Cash Per Share	$18.47
Equity (Book Value)	273.26M
Book Value Per Share	19.15
Working Capital	263.55M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$73.30 million and capital expenditures -$1.21 million, giving a free cash flow of -$74.51 million.

Operating Cash Flow	-73.30M
Capital Expenditures	-1.21M
Free Cash Flow	-74.51M
FCF Per Share	-$5.22

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Neurogene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-52.10%
Shareholder Yield	-52.10%
Earnings Yield	-28.01%
FCF Yield	-24.73%

Analyst Forecast

The average price target for Neurogene is $41.86, which is 98.30% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$41.86
Price Target Difference	98.30%
Analyst Consensus	Strong Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	114.66%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Neurogene has an Altman Z-Score of 8.01 and a Piotroski F-Score of 2.

Altman Z-Score	8.01
Piotroski F-Score	2